arrow
L

Linong Ji

北京大学人民医院
H指数:48
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and Safety of Chemically Synthesized Semaglutide Injection (HD1916) for the Treatment of Obesity: A Multicenter, Randomized, Phase III Trial

化学合成司美格鲁肽注射液(HD1916)治疗肥胖的疗效与安全性:一项多中心、随机、III期临床试验

2026-10-070
PRE
Effectiveness, Safety and Pharmacokinetics of BGM0504, a Dual GLP-1/GIP Receptor Agonist, in Chinese Adults With Overweight or Obesity Without Diabetes: A Phase 2 Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial

BGM0504,一种双重GLP-1/GIP受体激动剂,在中国超重或肥胖且无糖尿病成人中的有效性、安全性和药代动力学:一项Ⅱ期多中心、随机、双盲、安慰剂对照试验

2026-09-180
PRE
Efficacy and Hypoglycaemia Outcomes With Once-Weekly IcoSema Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A Post Hoc Analysis of the COMBINE 1–3 Trials

每周一次IcoSema与对照药在肾功能和肝功能不同的2型糖尿病患者中的疗效和低血糖结局:COMBINE 1–3试验的事后分析

2026-08-110
OAAI
Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double-Blind Phase II Trial

评价BGM0504在中国2型糖尿病成人中的安全性、有效性和药代动力学:一项多中心、随机、对照和双盲II期试验

2026-05-310
OAAI
CGM-derived efficacy and overall safety of once-weekly insulin efsitora alfa (efsitora) relative to day of administration in adults with type 2 diabetes

CGM衍生的疗效和每周一次的胰岛素efsitora alfa (efsitora) 相对于2型糖尿病成人给药日的总体安全性

2026-01-220
OAAI
Utility of continuous glucose monitoring in people with type 2 diabetes on insulin-based regimens in clinical practice: A case series and expert opinion

连续血糖监测在临床实践中接受胰岛素治疗方案2型糖尿病患者中的应用价值:病例系列研究和专家意见

2025-12-130
PRE
Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial

Mazdutide 与 Semaglutide 治疗 2 型糖尿病及肥胖:DREAMS-3 期 3 临床试验的背景、设计与基线数据

2025-11-011
PRE